Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC
Clinical trial NCT05351762 · UNKNOWN
Trial details
- NCT number
- NCT05351762
- Sponsor
- Xijing Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-01
- Primary completion
- 2024-05-30
- Enrollment
- 55
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.